Hereditary diffuse gastric cancer implications of genetic testing for screening and prophylactic surgery

Cancer

Volumn 113, Issue 7, 2008, Pages 1850-1856

  Cisco, Robin M ^a   Ford, James M ^a   Norton, Jeffrey A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

CDH1 mutations; Chromoendoscopy; Curative surgery; E cadherin; Familial breast Cancer; Prophylactic total gastrectomy

Indexed keywords

UVOMORULIN;

AUTOSOMAL DOMINANT DISORDER; BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CHROMOENDOSCOPY; FAMILIAL CANCER; GENE MUTATION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TOTAL STOMACH RESECTION;

CADHERINS; GASTRECTOMY; GENETIC SCREENING; HUMANS; MUTATION; STOMACH NEOPLASMS;

EID: 53949103559     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23650     Document Type: Review

References (52)

1. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003; 14(suppl 2):ii31-ii36.
2. Ford JM. Inherited susceptibility to gastric cancer: advances in genetics and guidelines for clinical management. ASCO Educational Sessions.2002:116-125.
3. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.
4. Crew KD, Neugut AI. Epidemiology of gastric Cancer. World J Gastroenterol, 2006;12:354-362.
5. Corley DA, Kubo A. Influence of site classification on cancer incidence rates: an analysis of gastric cardia carcinomas. J Natl Cancer Inst. 2004;96:1383-1387.
6. Caldas C, Cameiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. J Med Genet. 1999;36:873-880.
7. Suriano G, Yew S, Ferreira P, et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res. 2005;11:5401-5409.
8. Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508-517.
9. Stone J, Bevan S, Cunningham D, et al. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric Cancer. Br J Cancer. 1999;79(11-12):1935-1937.
10. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric Cancer. Nature. 1998;392:402-405.
11. Oliveira C, Seruca R, Caldas C. Genetic screening for hereditary diffuse gastric Cancer. Expert Rev Mol Diagn. 2003; 3:201-215.
12. Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric Cancer. JAMA. 2007;297:2360-2372.
13. Dussaulx-Garin L, Blayau M, Pagenault M, et al. A new mutation of E-cadherin gene in familial gastric linitis plastica cancer with extradigestive dissemination. Eur J Gastroenterol Hepatol. 2001;13:711-715.
14. Norton JA, Ham CM, Dam JV, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric Cancer. Ann Surg. 2007;245:873-879.
15. Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998;58:4086-4089.
16. Guilford PJ, Hopkins JB, Grady WM, et al. E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric Cancer. Hum Mutat. 1999;14:249-255.
17. Keller G, Vogelsang H, Becker I, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155:337-342.
18. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348-1353.
19. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal Cancer. Hum Mol Genet. 1999;8:607-610.
20. Shinmura K, Kohno T, Takahashi M, et al. Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis. 1999;20:1127-1131.
21. Yoon KA, Ku JL, Yang HK, Kim WH, Park SY, Park JG. Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet. 1999;44:177-180.
22. Rahman N, Stone JG, Coleman G, et al. Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene. Br J Cancer. 2000;82:568-570.
23. Salahshor S, Haixin L, Huo H, et al. Low frequency of E-cadherin alterations in familial breast Cancer. Breast Cancer Res. 2001;3:199-207.
24. Grunwald GB. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. Curr Opin Cell Biol. 1993;5:797-805.
25. Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 1994;54:3845-3852.
26. Birchmeier W. E-cadherin as a tumor (invasion) suppressor gene. Bioessays. 1995;17:97-99.
27. Carneiro F, Machado JC, Seruca R, Sobrinho-Simoes M. E-cadherin changes in gastric carcinoma. Histopathology. 1999;35:477-478.
28. Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric Cancer. Nat Genet. 2000;26:16-17.
29. Oliveira C, de Bruin J, Nabais S, et al. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene. 2004;23:2236-2240.
30. Suriano G, Oliveira C, Ferreira P, et al. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. Hum Mol Genet. 2003;12:575-582.
31. Masciari S, Larsson N, Senz J, et al. Germline E-cadherin mutations in familial lobular breast Cancer. J Med Genet. 2007;44:726-731.
32. Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203:681-687.
33. Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germline E-cadherin mutations. N Engl J Med. 2001;344:1904-1909.
34. Yamashina M. A variant of early gastric carcinoma. Histologic and histochemical studies of early signet ring cell carcinomas discovered beneath preserved surface epithelium. Cancer. 1986;58:1333-1339.
35. Shaw D, Blair V, Framp A, et al. Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut. 2005;54:461-468.
36. van Kouwen MC, Drenth JP, Oyen WJ, et al. [18F]Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res. 2004;10:6456-6459.
37. Arai M, Miki Y, Muto T, Kato Y. [Familial gastric Cancer.] Nippon Rinsho. 2001;59(suppl 4):251-256.
38. Bresciani C, Perez RO, Gama-Rodrigues J. Familial gastric Cancer. Arch Gastroenterol. 2003;40:114-117.
39. Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG. Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut. 2004;53:814-820.
40. Chen HC, Chu RY, Hsu PN, et al. Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas. Cancer Lett. 2003;201:97-106.
41. Newman EA, Mulholland MW. Prophylactic gastrectomy for hereditary diffuse gastric cancer syndrome. J Am Coll Surg. 2006;202:612-617.
42. Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ, et al. Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer. 2001;92:181-187.
43. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005;353:1105-1113.
44. Wells SA Jr, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg. 1994;220:237-247; discussion 247-250.
45. Wells SA Jr, Franz C. Medullary carcinoma of the thyroid gland. World J Surg. 2000;24:952-956.
46. Wells SA, Nevins JR. Evolving strategies for targeted cancer therapy-past, present, and future. J Natl Cancer Inst. 2004;96:980-981.
47. Wells SA Jr, Skinner MA. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes. 1998;106:29-34.
48. Lewis FR, Mellinger JD, Hayashi A, et al. Prophylactic total gastrectomy for familial gastric Cancer. Surgery. 2001;130:612-617; discussion 617-619.
49. Francis WP, Rodrigues DM, Perez NE, Lonardo F, Weaver D, Webber JD. Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric Cancer. JSLS. 2007; 11:142-147.
50. Oelschlager BK, Yigit T, Kaufman JA, Pellegrini CA. Hereditary diffuse gastric Cancer. Med Gen Med [serial online]. 2005;7:16.
51. Maehara Y, Baba H, Oda S, Kakeji Y, Emi Y, Sugimachi K. [Diagnosis and treatment for familial gastric cancer]. Can To Kagaku Ryoho. 2002;29:523-531.
52. Rogers W, Dobo E, Norton JA, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol. 2008;32:799-809.